cGMP-dependent protein kinases in drug discovery

Drug Discovery Today

Volumn 10, Issue 9, 2005, Pages 627-634

  Schlossmann, Jens ^a   Hofmann, Franz ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; 8 BROMO BETA PHENYL 1,N 2 ETHENO CYCLIC GUANOSINE MONOPHOSPHATE; 8 BROMO CYCLIC GMP; ANTHRANILIC ACID DERIVATIVE; BAY 418563; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENTEROTOXIN; GLYCERYL TRINITRATE; HMR 1766; INDAZOLE DERIVATIVE; ISOENZYME; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; KT 5823; NATRIURETIC FACTOR; NITRATE; NITRIC OXIDE; ORGANIC NITRATE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; PROTEIN KINASE INHIBITOR; S 3448; S 4448; SILDENAFIL; STAUROSPORINE DERIVATIVE; STREPTAVIDIN; TALADAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

ANGINA PECTORIS; ASTHMA; BLADDER; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DOWNSTREAM PROCESSING; DRUG TOLERANCE; ERECTILE DYSFUNCTION; FLUSHING; GASTROINTESTINAL TRACT; HEADACHE; HUMAN; INTESTINE SECRETION; LEARNING; MEAN ARTERIAL PRESSURE; MEMORY; NONHUMAN; PENILE BIOPSY; PULMONARY HYPERTENSION; RENIN RELEASE; REVIEW; SIDE EFFECT; SMOOTH MUSCLE RELAXATION; THROMBOCYTE AGGREGATION; THROMBOSIS; VASCULARIZATION; VISUAL IMPAIRMENT;

ANIMALS; BLOOD PLATELETS; CHEMISTRY, PHARMACEUTICAL; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MUSCLE, SMOOTH; NERVOUS SYSTEM; SIGNAL TRANSDUCTION;

EID: 18944382189     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03406-9     Document Type: Review

References (91)

1. Zhang J. Role of mitochondrial aldehyde dehydrogenase in nitroglycerin-induced vasodilation of coronary and systemic vessels: an intact canine model Circulation 110 2004 750 755
2. Chen Z. Identification of the enzymatic mechanism of nitroglycerin bioactivation Proc. Natl. Acad. Sci. U. S. A. 99 2002 8306 8311
3. Corbin J.D., Francis S.H. Pharmacology of phosphodiesterase-5 inhibitors Int. J. Clin. Pract. 56 2002 453 459
4. Kang K.K. DA-8159, a potent cGMP phosphodiesterase inhibitor, attenuates monocrotaline-induced pulmonary hypertension in rats Arch. Pharm. Res. 26 2003 612 619
5. Takimoto E. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy Nat. Med. 11 2005 214 222
6. Laties A., Zrenner E. Viagra (sildenafil citrate) and ophthalmology Prog. Retin. Eye Res. 21 2002 485 506
7. Rosen R.C., Kostis J.B. Overview of phosphodiesterase 5 inhibition in erectile dysfunction Am. J. Cardiol. 92 2003 9M 18M
8. Friebe A., Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase Circ. Res. 93 2003 96 105
9. Galle J. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity Br. J. Pharmacol. 127 1999 195 203
10. Nakane M. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1 Int. J. Impot. Res. 14 2002 121 127
11. Bischoff E. BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo. Urology 61 2003 464 467
12. Mullershausen F. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272 Circulation 109 2004 1711 1713
13. Stasch J.P. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies Br. J. Pharmacol. 135 2002 344 355
14. Stasch J.P. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle Br. J. Pharmacol. 136 2002 773 783
15. Witte K. Nitric oxide-sensitive soluble guanylyl cyclase activity is preserved in internal mammary artery of type 2 diabetic patients Diabetes 53 2004 2640 2644
16. Hofmann F. Rising behind NO: cGMP-dependent protein kinases J. Cell Sci. 113 2000 1671 1676
17. Hofmann F. The biology of cyclic GMP-dependent protein kinases J. Biol. Chem. 280 2005 1 4
18. Schlossmann J. Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Ibeta Nature 404 2000 197 201
19. Surks H.K. Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase I Science 286 1999 1583 1587
20. Geiselhöringer A. Distribution of IRAG and cGKI-isoforms in murine tissues FEBS Lett. 575 2004 19 22
21. Schlossmann J. Insights into cGMP signalling derived from cGMP Kinase knockout mice Frontiers in Bioscience 10 2005 1279 1289
22. Schlossmann J. Signaling through NO and cGMP-dependent protein kinases Ann. Med. 35 2003 21 27
23. Ammendola A. Molecular determinants of the interaction between the inositol 1,4,5-trisphosphate receptor-associated cGMP kinase substrate (IRAG) and cGMP kinase Ibeta J. Biol. Chem. 276 2001 24153 24159
24. Geiselhöringer A. IRAG is essential for relaxation of receptor-triggered smooth muscle contraction by cGMP Kinase EMBO J. 23 2004 4222 4231
25. Sausbier M. Mechanisms of NO/cGMP-dependent vasorelaxation Circ. Res. 87 2000 825 830
26. Tang M.K. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure Nat. Med. 9 2003 1506 1515
27. Sun X. RGS2 is a mediator of nitric oxide action on blood pressure and vasoconstrictor signaling Mol. Pharmacol. 67 2005 631 639
28. Xia C. Phosphorylation and regulation of G-protein-activated phospholipase C-beta 3 by cGMP-dependent protein kinases J. Biol. Chem. 276 2001 19770 19777
29. Wooldridge A.A. Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of Serine 695 in response to cyclic nucleotides J. Biol. Chem. 279 2004 34496 34504
30. Ellerbroek S.M. Serine phosphorylation negatively regulates RhoA in vivo. J. Biol. Chem. 278 2003 19023 19031
31. Mullershausen F. In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation Mol. Biol. Cell 15 2004 4023 4030
32. Cornwell T.L. Regulation of sarcoplasmic reticulum protein phosphorylation by localized cyclic GMP-dependent protein kinase in vascular smooth muscle cells Mol. Pharmacol. 40 1991 923 931
33. Lalli M.J. [Ca2+]i homeostasis and cyclic nucleotide relaxation in aorta of phospholamban-deficient mice Am. J. Physiol. 277 1999 H963 H970
34. Kwan H.Y. Regulation of canonical transient receptor potential isoform 3 (TRPC3) channel by protein kinase G Proc. Natl. Acad. Sci. U. S. A. 101 2004 2625 2630
35. Walker L.A. Site-specific phosphorylation and point mutations of telokin modulate its Ca2+-desensitizing effect in smooth muscle J. Biol. Chem. 276 2001 24519 24524
36. Schulz E. Functional and biochemical analysis of endothelial (dys) function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment Circulation 105 2002 1170 1175
37. Aszodi A. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function EMBO J. 18 1999 37 48
38. Huber A. Cysteine-rich protein 2, a novel substrate for cGMP kinase I in enteric neurons and intestinal smooth muscle J. Biol. Chem. 275 2000 5504 5511
39. Pfeifer A. Defective smooth muscle regulation in cGMP kinase I-deficient mice EMBO J. 17 1998 3045 3051
40. Wolfsgruber W. A proatherogenic role for cGMP-dependent protein kinase in vascular smooth muscle cells Proc. Natl. Acad. Sci. U. S. A. 100 2003 13519 13524
41. Ny L. Impaired relaxation of stomach smooth muscle in mice lacking cyclic GMP-dependent protein kinase I Br. J. Pharmacol. 129 2000 395 401
42. Persson K. Functional characteristics of urinary tract smooth muscles in mice lacking cGMP protein kinase type I Am. J. Physiol. Regul. Integr. Comp. Physiol. 279 2000 R1112 R1120
43. Meredith A.L. Overactive bladder and incontinence in the absence of the BK large conductance Ca2+-activated K+ channel J. Biol. Chem. 279 2004 36746 36752
44. Corbin J.D., Francis S.H. Pharmacology of phosphodiesterase-5 inhibitors Int. J. Clin. Pract. 56 2002 453 459
45. Hedlund P. Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice Proc. Natl. Acad. Sci. U. S. A. 97 2000 2349 2354
46. Massberg S. Increased adhesion and aggregation of platelets lacking cyclic guanosine 3′,5′-monophosphate kinase I J. Exp. Med. 189 1999 1255 1264
47. Li Z. A stimulatory role for cGMP-dependent protein kinase in platelet activation Cell 112 2003 77 86
48. Tertyshnikova S. cGMP inhibits IP3-induced Ca2+ release in intact rat megakaryocytes via cGMP- and cAMP-dependent protein kinases J. Physiol. 512 1998 89 96
49. Reid H.M., Kinsella B.T. The alpha, but not the beta, isoform of the human thromboxane A2 receptor is a target for nitric oxide-mediated desensitization. Independent modulation of Tp alpha signaling by nitric oxide and prostacyclin J. Biol. Chem. 278 2003 51190 51202
50. Massberg S. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice Blood 103 2004 136 142
51. Butt E. Heat shock protein 27 is a substrate of cGMP-dependent protein kinase in intact human platelets: phosphorylation-induced actin polymerization caused by HSP27 mutants J. Biol. Chem. 276 2001 7108 7113
52. Feil R. Function of cGK in the nervous system Rev. Neurosci 16 2005 23 42
53. Kleppisch T. Hippocampal cGMP-dependent protein kinase I supports an age- and protein synthesis-dependent component of long-term potentiation but is not essential for spatial reference and contextual memory J. Neurosci. 23 2003 6005 6012
54. Wang H.G. Presynaptic and postsynaptic roles of NO, cGK, and RhoA in long-lasting potentiation and aggregation of synaptic proteins Neuron 45 2005 389 403
55. Xue J. Phosphorylation of septin 3 on Ser-91 by cGMP-dependent protein kinase-I in nerve terminals Biochem. J. 381 2004 753 760
56. Feil R. Impairment of LTD and cerebellar learning by Purkinje cell-specific ablation of cGMP-dependent protein kinase I J. Cell Biol. 163 2003 295 302
57. Wagner L.E. Phosphorylation of type-1 inositol 1,4,5-trisphosphate receptors by cyclic nucleotide-dependent protein kinases: a mutational analysis of the functionally important sites in the S2+ and S2- splice variants J. Biol. Chem. 278 2003 45811 45817
58. Endo S. Thr123 of rat G-substrate contributes to its action as a protein phosphatase inhibitor Neurosci. Res. 45 2003 79 89
59. Schmidtko A. Inhibition of cyclic guanosine 5′-monophosphate- dependent protein kinase I (PKG-I) in lumbar spinal cord reduces formalin-induced hyperalgesia and PKG upregulation Nitric Oxide 8 2003 89 94
60. Tegeder I. Reduced inflammatory hyperalgesia with preservation of acute thermal nociception in mice lacking cGMP-dependent protein kinase I Proc. Natl. Acad. Sci. U. S. A. 101 2004 3253 3257
61. Vaandrager A.B. Membrane targeting of cGMP-dependent protein kinase is required for cystic fibrosis transmembrane conductance regulator Cl- channel activation Proc. Natl. Acad. Sci. U. S. A. 95 1998 1466 1471
62. Pfeifer A. Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II Science 274 1996 2082 2086
63. Miyazawa T. Cyclic GMP-dependent protein kinase II plays a critical role in C-type natriuretic peptide-mediated endochondral ossification Endocrinology 143 2002 3604 3610
64. Chikuda H. Cyclic GMP-dependent protein kinase II is a molecular switch from proliferation to hypertrophic differentiation of chondrocytes Genes Dev. 18 2004 2418 2429
65. Schricker K., Kurtz A. Liberators of NO exert a dual effect on renin secretion from isolated mouse renal juxtaglomerular cells Am. J. Physiol. 265 1993 F180 F186
66. Gambaryan S. cGMP-dependent protein kinase type II regulates basal level of aldosterone production by zona glomerulosa cells without increasing expression of the steroidogenic acute regulatory protein gene J. Biol. Chem. 278 2003 29640 29648
67. Nikolaev V.O. Real-time monitoring of the PDE2 activity of live cells: hormone-stimulated cAMP hydrolysis is faster than hormone-stimulated cAMP synthesis J. Biol. Chem. 280 2005 1716 1719
68. Oster H. cGMP-dependent protein kinase II modulates mPer1 and mPer2 gene induction and influences phase shifts of the circadian clock Curr. Biol. 13 2003 725 733
69. Tischkau S.A. Protein kinase G type II is required for night-to-day progression of the mammalian circadian clock Neuron 43 2004 539 549
70. Schwede F. Cyclic nucleotide analogs as biochemical tools and prospective drugs Pharmacol. Ther. 87 2000 199 226
71. Gamm D.M. The type II isoform of cGMP-dependent protein kinase is dimeric and possesses regulatory and catalytic properties distinct from the type I isoforms J. Biol. Chem. 270 1995 27380 27388
72. Wei J.Y. Substituted cGMP analogs can act as selective agonists of the rod photoreceptor cGMP-gated cation channel J. Mol. Neurosci. 10 1998 53 64
73. Butt E. Analysis of the functional role of cGMP-dependent protein kinase in intact human platelets using a specific activator 8-para-chlorophenylthio- cGMP Biochem. Pharmacol. 43 1992 2591 2600
74. Butt E. Inhibition of cyclic GMP-dependent protein kinase-mediated effects by (Rp)-8-bromo-PET-cyclic GMPS Br. J. Pharmacol. 116 1995 3110 3116
75. Butt E. (Rp)-8-pCPT-cGMPS, a novel cGMP-dependent protein kinase inhibitor Eur. J. Pharmacol. 269 1994 265 268
76. Kase H. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases Biochem. Biophys. Res. Commun. 142 1987 436 440
77. Burkhardt M. KT5823 inhibits cGMP-dependent protein kinase activity in vitro but not in intact human platelets and rat mesangial cells J. Biol. Chem. 275 2000 33536 33541
78. Tegge W.J., Frank R. Analysis of protein kinase substrate specificity by the use of peptide libraries on cellulose paper (SPOT-method) Methods Mol. Biol. 87 1998 99 106
79. Dostmann W.R. Delineation of selective cyclic GMP-dependent protein kinase Ialpha substrate and inhibitor peptides based on combinatorial peptide libraries on paper Pharmacol. Ther. 82 1999 373 387
80. Dostmann W.R. Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha inhibit NO-induced cerebral dilation Proc. Natl. Acad. Sci. U. S. A. 97 2000 14772 14777
81. Taylor M.S. Inhibition of cGMP-dependent protein kinase by the cell-permeable peptide DT-2 reveals a novel mechanism of vasoregulation Mol. Pharmacol. 65 2004 1111 1119
82. Bader B. A cGMP-dependent protein kinase assay for high throughput screening based on time-resolved fluorescence resonance energy transfer J. Biomol. Screen. 6 2001 255 264
83. Lawson C.A. Selective reduction of PVR by inhalation of a cGMP analogue in a porcine model of pulmonary hypertension Am. J. Physiol. 268 1995 H2056 H2062
84. Maeda T. Analogs of cyclic nucleotides in rat liver preservation Transplantation 66 1998 844 851
85. Pinsky D.J. The nitric oxide/cyclic GMP pathway in organ transplantation: critical role in successful lung preservation Proc. Natl. Acad. Sci. U. S. A. 91 1994 12086 12090
86. Hillinger S. 8-Br-cGMP is superior to prostaglandin E1 for lung preservation Ann. Thorac. Surg. 68 1999 1138 1142
87. Gambaryan S. Potent inhibition of human platelets by cGMP analogs independent of cGMP-dependent protein kinase Blood 103 2004 2593 2600
88. Marshall S.J. GPIb-dependent platelet activation is dependent on Src kinases but not MAP kinase or cGMP-dependent kinase Blood 103 2004 2601 2609
89. Sung Y.J. A neuronal isoform of protein kinase G couples mitogen-activated protein kinase nuclear import to axotomy-induced long-term hyperexcitability in Aplysia sensory neurons J. Neurosci. 24 2004 7583 7595
90. Scheiner R. Activity of cGMP-dependent protein kinase (PKG) affects sucrose responsiveness and habituation in Drosophila melanogaster. Learn. Mem. 11 2004 303 311
91. Werner C. Importance of NO/cGMP signalling via cGMP-dependent protein kinase II for controlling emotionality and neurobehavioural effects of alcohol Eur. J. Neurosci. 20 2004 3498 3506